Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TongBi Capsule** is an orally administered traditional Chinese medicine product developed by Shandong Runzhong Pharmaceutical for joint disease. It has been evaluated in a randomized, double-blind, placebo-controlled post-marketing Phase 3 study in adults with knee osteoarthritis. In an ovalbumin-induced rabbit rheumatoid arthritis model, oral TongBi Capsule reduced knee swelling and local temperature, improved synovial and cartilage pathology, and was associated with lower serum interleukin-1 and tumor necrosis factor-alpha concentrations. Its precise active-ingredient composition and direct molecular targets were not established in the available public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TongBi Capsule.